WO2022179535A1 - Anticorps monoclonal contre la protéine nucléocapsidique du sars-cov-2, son procédé de préparation et son utilisation - Google Patents

Anticorps monoclonal contre la protéine nucléocapsidique du sars-cov-2, son procédé de préparation et son utilisation Download PDF

Info

Publication number
WO2022179535A1
WO2022179535A1 PCT/CN2022/077540 CN2022077540W WO2022179535A1 WO 2022179535 A1 WO2022179535 A1 WO 2022179535A1 CN 2022077540 W CN2022077540 W CN 2022077540W WO 2022179535 A1 WO2022179535 A1 WO 2022179535A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
variable region
chain variable
acid sequence
Prior art date
Application number
PCT/CN2022/077540
Other languages
English (en)
Chinese (zh)
Inventor
丁莉丹
陈晖�
钱永洪
Original Assignee
南京金斯瑞生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京金斯瑞生物科技有限公司 filed Critical 南京金斯瑞生物科技有限公司
Publication of WO2022179535A1 publication Critical patent/WO2022179535A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens

Definitions

  • the invention belongs to the field of virus detection and diagnosis, and relates to a monoclonal antibody against SARS-CoV-2 nucleocapsid protein (N protein).
  • the invention also relates to the preparation method and use of the anti-SARS-CoV-2 nucleocapsid protein monoclonal antibody.
  • Severe acute respiratory syndrome coronavirus (Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) belongs to the beta genus of coronavirus, with a diameter of 60nm to 140nm, with a capsule, and the particles are round or oval, often polymorphic Its genetic characteristics are significantly different from SARSr-CoV and MERSrCoV. SARS-CoV-2 is the seventh coronavirus discovered so far that can infect humans, and the third one that can cause acute respiratory disease. The disease caused by this virus is called novel coronavirus disease 2019 (coronavirus disease 2019, COVID-19), and it has become a global epidemic. As of 19 January 2021, more than 93 million cases of COVID-19 and nearly 2 million deaths have been reported to WHO.
  • SARS-CoV-2 is an enveloped virus with a single-stranded positive-sense RNA genome. Its genomic RNA is about 30kb and contains 12 open reading frames (ORFs).
  • the main encoded structural proteins are envelope protein (Envelope protein, E protein). ), spike protein (spike protein, S protein), membrane protein (membrane protein, M protein) and nucleocapsid protein (nucleocapsid protein, N protein).
  • nucleic acid testing requires relatively high throat or nasopharyngeal swab sampling. Improper sample collection techniques, storage conditions, and PCR operations may result in false negative and false positive results, resulting in significant delays in early diagnosis and follow-up management. Prompt life support treatment and preventive quarantine pose serious challenges.
  • the PCR nucleic acid detection method is responsible for the operation, and the cycle is relatively long. Therefore, the development of antibody-based detection methods is particularly important.
  • the present invention provides an anti-SARS-CoV-2 nucleocapsid (N) protein monoclonal antibody or a functional fragment thereof, the antibody or functional fragment thereof comprising a heavy chain variable region and a light chain variable region district, of which
  • the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3,
  • the HCDR1 comprises an amino acid sequence selected from the group consisting of amino acid sequences shown in SEQ ID NO: 15, 21, 27, 33, 39, 45 or 51 or the amino acid sequence shown comprises up to three (eg, one, two or three) amino acid mutations
  • the variant of comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 16, 22, 28, 34, 40, 46 or 52 or the amino acid sequence shown comprises up to three (e.g., one, two or three) a) variant of amino acid mutation
  • the HCDR3 comprises an amino acid sequence selected from the group consisting of amino acid sequences shown in SEQ ID NO: 17, 23, 29, 35, 41, 47 or 53 or the amino acid sequence shown comprises up to three (e.g., one, two or three) amino acid mutated variants; and
  • the light chain variable region comprises LCDR1, LCDR2 and LCDR3,
  • the LCDR1 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 18, 24, 30, 36, 42, 48 or 54 or the amino acid sequence shown comprises up to three (e.g., one, two or three) amino acids Mutated variants;
  • the LCDR2 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 19, 25, 31, 37, 43, 49 or 55 or the amino acid sequence shown comprises up to three (e.g., one, two or three) amino acid mutated variants;
  • the LCDR3 sequence comprises an amino acid sequence selected from the group consisting of amino acid sequences shown in SEQ ID NO: 20, 26, 32, 38, 44, 50 or 56 or the amino acid sequence shown comprises up to three (e.g. , one, two or three) amino acid mutated variants.
  • the HCDR1 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 15, 21, 27, 33, 39, 45, or 51
  • the HCDR2 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 22 , the amino acid sequence shown in 28, 34, 40, 46 or 52
  • the HCDR3 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 17, 23, 29, 35, 41, 47 or 53
  • the LCDR1 comprises an amino acid sequence selected from SEQ ID NO: 18, 24, 30, 36, 42, 48 or 54
  • the LCDR2 sequence comprises an amino acid sequence selected from SEQ ID NO: 19, 25, 31, 37, 43, 49 or
  • the amino acid sequence shown in 55 the LCDR3 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 20, 26, 32, 38, 44, 50 or 56.
  • the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are selected from the sequence:
  • the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 15, 16 and 17, respectively, or a variant in which the shown amino acid sequences comprise up to three (eg, one, two or three) amino acid mutations, respectively and LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 18, 19 and 20, respectively, or variants in which the shown amino acid sequences comprise up to three (e.g., one, two or three) amino acid mutations, respectively ;
  • the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 21, 22 and 23, respectively, or a variant in which the shown amino acid sequences comprise up to three (eg, one, two or three) amino acid mutations, respectively and LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences shown in SEQ ID NOs: 24, 25 and 26, respectively, or variants in which the shown amino acid sequences comprise up to three (e.g., one, two or three) amino acid mutations, respectively ;
  • the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 27, 28 and 29, respectively, or a variant in which the shown amino acid sequences comprise up to three (eg, one, two or three) amino acid mutations, respectively and LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 30, 31 and 32, respectively, or variants in which the shown amino acid sequences comprise up to three (e.g., one, two or three) amino acid mutations, respectively ;
  • the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 33, 34 and 35, respectively, or a variant in which the shown amino acid sequences comprise up to three (eg, one, two or three) amino acid mutations, respectively and LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences shown in SEQ ID NOs: 36, 37 and 38, respectively, or variants in which the shown amino acid sequences comprise up to three (e.g., one, two or three) amino acid mutations, respectively ;
  • the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 39, 40 and 41, respectively, or a variant in which the shown amino acid sequences comprise up to three (eg, one, two or three) amino acid mutations, respectively and LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 42, 43 and 44, respectively, or variants in which the shown amino acid sequences comprise up to three (e.g., one, two or three) amino acid mutations, respectively ;
  • the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 45, 46 and 47, respectively, or a variant in which the shown amino acid sequences comprise up to three (eg, one, two or three) amino acid mutations, respectively and LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 48, 49 and 50, respectively, or variants in which the shown amino acid sequences comprise up to three (e.g., one, two or three) amino acid mutations, respectively ;or
  • the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 51, 52 and 53, respectively, or a variant in which the shown amino acid sequences comprise up to three (eg, one, two or three) amino acid mutations, respectively and LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 54, 55 and 56, respectively, or variants in which the shown amino acid sequences comprise up to three (e.g., one, two or three) amino acid mutations, respectively .
  • the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are selected from the sequence:
  • the HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 15, 16 and 17 and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 18, 19 and 20;
  • the HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 21, 22 and 23 and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 24, 25 and 26;
  • HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO:27, 28 and 29 and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO:30, 31 and 32;
  • the HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 33, 34 and 35 and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 36, 37 and 38;
  • the HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 39, 40 and 41 and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 42, 43 and 44;
  • HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 45, 46 and 47, respectively; and LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 48, 49 and 50, respectively; or
  • the HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 51, 52 and 53 and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 54, 55 and 56.
  • the heavy chain variable region sequence comprises an amino acid sequence that is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11 or 13; and the The light chain variable region sequence comprises an amino acid sequence that is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 2, 4, 6, 8, 10, 12 or 14.
  • the heavy chain variable region sequence comprises at least 80%, 81%, 82%, 83% of the amino acid sequence set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11 or 13 , 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% consistency
  • the amino acid sequence of ; the light chain variable region sequence comprises at least 80%, 81%, 82%, 83%, 84 %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acids sequence.
  • the heavy chain variable region sequence comprises the amino acid sequence set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11 or 13;
  • the light chain variable region sequence comprises SEQ ID NO: The amino acid sequence shown in 2, 4, 6, 8, 10, 12 or 14.
  • the heavy chain variable region and light chain variable region are selected from the following sequences:
  • the heavy chain variable region comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% of the sequence shown in SEQ ID NO: 1 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence comprising the light chain variable region comprising the same as SEQ ID NO: 2
  • the sequence shown has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% , 95%, 96%, 97%, 98% or 99% identical amino acid sequences;
  • variable region of the heavy chain comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% of the sequence shown in SEQ ID NO: 3 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence comprising the light chain variable region comprising the same as SEQ ID NO: 4
  • the sequence shown has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% , 95%, 96%, 97%, 98% or 99% identical amino acid sequences;
  • variable region of the heavy chain comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% of the sequence shown in SEQ ID NO: 5 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence comprising the light chain variable region comprising the same as SEQ ID NO: 6
  • the sequence shown has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% , 95%, 96%, 97%, 98% or 99% identical amino acid sequences;
  • the heavy chain variable region comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% of the sequence shown in SEQ ID NO: 7 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence comprising the light chain variable region comprising the same as SEQ ID NO: 8
  • the sequence shown has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% , 95%, 96%, 97%, 98% or 99% identical amino acid sequences;
  • variable region of the heavy chain comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% of the sequence shown in SEQ ID NO: 9 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence comprising the light chain variable region comprising the same as SEQ ID NO: 10
  • the sequence shown has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% , 95%, 96%, 97%, 98% or 99% identical amino acid sequences;
  • the heavy chain variable region comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% of the sequence shown in SEQ ID NO: 11 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence comprising the light chain variable region comprising the same as SEQ ID NO: 12
  • the sequence shown has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% , 95%, 96%, 97%, 98% or 99% identical amino acid sequences; or
  • variable region of the heavy chain comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% of the sequence shown in SEQ ID NO: 13 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence comprising the light chain variable region comprising the same as SEQ ID NO: 14
  • the sequence shown has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% , 95%, 96%, 97%, 98% or 99% identical amino acid sequences.
  • the heavy chain variable region and light chain variable region are selected from the following sequences:
  • the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:1, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:2;
  • the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:3, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:4;
  • the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:5, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:6;
  • the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:7, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:8;
  • the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:9, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:10;
  • the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 11 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 12;
  • the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 13
  • the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 14.
  • the heavy chain variable region and light chain variable region are selected from the following sequences:
  • the present invention provides an isolated polynucleotide encoding the above-mentioned anti-SARS-CoV-2 N protein monoclonal antibody or a functional fragment thereof.
  • the polynucleotide comprises a nucleotide sequence encoding the heavy chain variable region of the above-mentioned anti-SARS-CoV-2 N protein monoclonal antibody or a functional fragment thereof, and encoding the anti-SARS-CoV-2 2 The nucleotide sequence of the light chain variable region of the N protein monoclonal antibody or its functional fragment.
  • the present invention provides an expression vector comprising the polynucleotide.
  • the present invention provides a host cell or cell-free expression system comprising the expression vector.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the anti-SARS-CoV-2 N protein monoclonal antibody or a functional fragment thereof and a pharmaceutically acceptable carrier.
  • the present invention provides the application of the anti-SARS-CoV-2 N protein monoclonal antibody or its functional fragment in the preparation of a drug for the treatment of coronavirus.
  • the present invention provides a kit for detecting coronavirus, which comprises the monoclonal antibody or its functional fragment.
  • the coronavirus is selected from SARS-CoV, MERS-CoV or SARS-CoV-2, preferably SARS-CoV-2. In other embodiments, the coronavirus is SARS-CoV-2.
  • the present invention provides a method for preparing an anti-SARS-CoV-2 N protein monoclonal antibody or a functional fragment thereof, comprising:
  • PBMC peripheral blood mononuclear Cell
  • variable region coding sequence for recombinant antibody production to obtain a functional anti-SARS-CoV-2 N protein monoclonal antibody.
  • the monoclonal antibody is a rabbit-derived, chimeric, humanized or human antibody. In some preferred embodiments, the monoclonal antibody is of rabbit origin. In other preferred embodiments, the monoclonal antibody is humanized.
  • the monoclonal antibody against the SARS-CoV-2 N protein provided by the present invention can be combined with the N protein, and can be used for the detection of the SARS-CoV-2 virus antigen.
  • the monoclonal antibodies provided can recognize 5 epitopes of antigens, and the diversity of antibodies provides convenience for the development of detection kits.
  • the paired detection of the monoclonal antibodies NR8105 and NR1245 of the provided N recombinant purified protein has a sensitivity of 0-40 pg/ml.
  • Fig. 1 is the result figure of the rabbit serum titer detection result after immunization
  • Figure 2 is a graph showing the identification results of SDS-PAGE after monoclonal antibody purification
  • Fig. 3 is the EC50 detection result graph of monoclonal antibody
  • Figure 4 is a graph showing the pairing results of monoclonal antibodies NR8105 and NR1245;
  • Figure 5 is a graph showing the pairing results of monoclonal antibodies NR8105 and NR2604.
  • the present invention relates to a functional monoclonal antibody to the N protein of the virus SARS-CoV-2, and the embodiments of the present invention will be described in detail below with reference to examples. Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
  • novel coronavirus SARS-CoV-2
  • 2019-nCoV belongs to the beta genus coronavirus, with an envelope, round or oval particles, often pleomorphic, 60-140nm in diameter . Its genetic characteristics are significantly different from SARSr-CoV and MERSr-CoV. Studies have shown that it shares more than 85% homology with bat SARS-like coronavirus (bat-SL-CoVZC45). When isolated and cultured in vitro, 2019-nCov can be found in human respiratory epithelial cells in about 96 hours, while it takes about 6 days to isolate and culture in Vero E6 and Huh-7 cell lines.
  • antibody is intended to refer to an immunoglobulin molecule consisting of four polypeptide chains (wherein two heavy (H) and two light (L) chains are connected to each other by disulfide bonds (ie "complete antibody molecule")) , and multimers thereof (eg, IgM) or antigen-binding fragments thereof.
  • Each heavy chain consists of a heavy chain variable region ("HCVR” or “VH”) and a heavy chain constant region (consisting of the domains CH1, CH2 and CH3).
  • Each light chain consists of a light chain variable region (“LCVR” or “VL”) and a light chain constant region (CL).
  • VH and VL regions can be further subdivided into hypervariable regions called complementarity determining regions (CDRs) with more conserved regions interposed therebetween called framework regions (FRs).
  • CDRs complementarity determining regions
  • FRs framework regions
  • Each VH and VL consists of three CDRs and four FRs, arranged from amino terminus to hydroxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the FRs of the antibody may be identical to human germline sequences or may be naturally or artificially modified.
  • the term "monoclonal antibody” refers to a homogeneous antibody directed against only a particular epitope. Each monoclonal antibody is directed against a single epitope on an antigen, in contrast to typical polyclonal antibody preparations that include different antibodies directed against different antigenic determinants (epitopes).
  • the modifier "monoclonal” denotes a uniform characteristic of an antibody and is not to be construed as requiring that the antibody be produced by any particular method.
  • the monoclonal antibodies of the present invention are preferably produced by recombinant DNA methods, or obtained by screening methods as described elsewhere herein.
  • mutation refers to a monoclonal antibody or functional fragment thereof comprising an alteration of one or more (several) amino acid residues at one or more (several) positions, ie, a substitution, insertion and/or deletion of a polypeptide.
  • a substitution refers to replacing an amino acid occupying a position with a different amino acid;
  • a deletion refers to removing an amino acid occupying a position; and
  • an insertion refers to adding 1-3 amino acids adjacent to and after the amino acid occupying a position.
  • isolated polynucleotide refers to a polynucleotide that is not in a naturally occurring state in nature, including polynucleotides isolated from nature (including in vivo) by biological techniques, as well as artificially synthesized polynucleotides.
  • An isolated polynucleotide can be genomic DNA, cDNA, mRNA, or other synthetic RNA, or a combination thereof. It should be pointed out that those skilled in the art can design the provided nucleotide sequences with different nucleotide sequences according to the amino acid sequences of the heavy chain variable region and light chain variable region provided herein and based on the degeneracy of codons. nucleotide sequences, but both encode the same amino acid sequence. These altered nucleotide sequences are also included within the scope of the present invention.
  • vector when referring to a polynucleotide refers to any molecule (eg, nucleic acid, plasmid or virus, etc.) used to transfer information encoded by a nucleotide into a host cell.
  • expression vector or “expression cassette” refers to a vector suitable for expressing a gene of interest (nucleotide sequence to be expressed) in a host cell, usually including parts of the gene of interest, promoter, terminator, marker gene and the like.
  • host cell refers to a cell that has been or is capable of being transformed with a nucleic acid sequence and thereby expressing a selected gene of interest.
  • the term includes progeny of a parent cell, whether or not the progeny is identical in morphology or genetic composition to the original parent cell, so long as the progeny has the selected gene of interest.
  • Commonly used host cells include bacteria, yeast, mammalian cells, and the like.
  • antibody functional fragment means antigen-binding fragments and antibody analogs of antibodies, which typically include at least a portion of the antigen-binding or variable regions (eg, one or more CDRs) of the parental antibody. Antibody fragments retain at least some of the binding specificity of the parent antibody.
  • antibody fragments capable of binding the coronavirus spike (S) protein or portion thereof include, but are not limited to, sdAb (single domain antibodies), Fab (eg, antibodies obtained by papain digestion), F(ab')2 ( For example, by pepsin digestion), Fv or scFv (eg by molecular biology techniques).
  • pharmaceutically acceptable carrier includes any and all solvents, dispersions, coatings, isotonic and sustained release agents of antibacterial and antifungal agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the Standard References in Remington's Pharmaceutical Sciences, latest edition, which is hereby incorporated by reference in its entirety. Examples of suitable carriers or diluents include, but are not limited to, water, saline solution, ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and hydrophobic vehicles such as fixed oils can also be employed.
  • the use of pharmaceutically active media and agents is well known in the art. Except for those conventional media or agents that are incompatible with the active ingredient, its use in the ingredients can achieve the desired effect.
  • amino acid substitution refers to the replacement of existing amino acid residues with different amino acid residues in a predetermined (original) amino acid sequence.
  • amino acid substitutions are preferably made in accordance with the substitutions shown below:
  • Percent (%) amino acid sequence identity with respect to antibody sequences is defined as comparing sequences and introducing gaps where necessary to obtain maximum percent sequence identity, and without considering any conservative substitutions as part of sequence identity, among candidate sequences The percentage of amino acid residues that are identical to amino acid residues in a particular peptide or polypeptide sequence. Alignment of sequences to determine percent amino acid sequence identity can be performed in a variety of ways that are within the skill in the art, eg, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to obtain maximal alignment over the full length of the sequences being compared.
  • administer and “treat” in reference to an animal, human, subject, cell, tissue, organ or biological fluid, it refers to combining an exogenous drug, therapeutic agent, diagnostic agent or composition with the animal, human, subject, or biological fluid. Person, cell, tissue, organ or biological fluid contact.
  • administering and “treatment” can refer to, for example, therapeutic methods, pharmacokinetic methods, diagnostic methods, research methods, and experimental methods. Treating the cells includes contacting the agent with the cells and contacting the agent with a fluid, wherein the fluid is in contact with the cells.
  • administering and “treating” also mean in vitro and ex vivo treatment of cells, eg, by agents, diagnostic agents, binding compositions, or by other cells.
  • subject refers to an animal, preferably a mammal, more preferably a human, in need of alleviation, prevention and/or treatment of a disease or disorder such as a viral infection.
  • the term includes human subjects with or at risk of infection with a coronavirus such as SARS-CoV-2.
  • the term “effective amount” refers to an amount that produces function or activity in humans and/or animals and is acceptable to humans and/or animals.
  • “Pharmaceutically acceptable carrier” refers to a carrier for administration, including various excipients, diluents and buffers, etc., which are suitable for human and/or animal administration without excessive adverse side effects, and at the same time Suitable for maintaining the viability of a drug or active agent located therein.
  • the animal immunization antigen adopts recombinant SARS-CoV-2 N protein (Genscript, Z03480). New Zealand white rabbits numbered 18401 were immunized subcutaneously with 200 ⁇ g of N fusion protein. Subsequently, the immunization was repeated every other week, so that the experimental rabbits were boosted 3 times in total. Rabbit serum titers reached more than 105 after 3 immunizations (Fig. 1).
  • the enriched cells were plated into a 96-well cell culture plate plated with feeder cells in advance at a density of 10 cells per well. Incubate the plate at 37 °C in 5% CO . After 6 days of incubation, fresh medium was replaced, and on day 7 the overnight culture supernatants were collected and tested for the presence of antibodies against the extramembrane region of the N protein using ELISA binding as described below.
  • Indirect ELISA was used to assess the binding ability of the antibody to the N protein in the supernatant.
  • ELISA plates were coated with 100 ⁇ l/well of recombinant N protein at 1 ⁇ g/ml in PBS overnight at 4°C. Plates were washed with PBS-T (0.05% Tween) and blocked with 150 ⁇ l/well of PBST containing 1% BSA for 1 hour at 37°C. The blocking solution was then discarded and 100 ⁇ l of B cell culture supernatant was added to each plate, followed by incubation at 37°C for 1 hour.
  • RNA from total cells in wells with an OD value greater than 1.0 was extracted using TRIzol (Life Technology, 15596-026), and reverse transcribed into cDNA using universal primers (Prime ScriptTM 1st Strand cDNA Synthesis Kit, Takara).
  • the rabbit immunoglobulin heavy and light chain V-region fragments were subsequently amplified by antibody signal peptide and constant region-specific primers, and the resulting PCR fragments were homologously recombined into the pCDNA3.4 vector using vector-specific primer pairs Inserts were sequenced. Finally, the unique V-region protein amino acid sequences and plasmids of RN5502, RN8105, RN0510, RN2604, RN1245, RN1279, and RN1248 clones were obtained.
  • RN5502 heavy chain variable region amino acid sequence (SEQ ID NO: 1):
  • RN8105 heavy chain variable region amino acid sequence (SEQ ID NO: 3):
  • RN0510 heavy chain variable region amino acid sequence (SEQ ID NO: 5):
  • RN2604 heavy chain variable region amino acid sequence (SEQ ID NO: 7):
  • RN1245 heavy chain variable region amino acid sequence (SEQ ID NO: 9):
  • Plasmids containing antibody heavy and light chains, respectively, were co-transfected into HEK293-6E (NRC, 11565) cells, and after culturing in shake flasks at 37°C for 6 days, the supernatant was collected for antibody purification.
  • the Protein A column was equilibrated with buffer containing 0.05M Tris and 1.5M NaCl (pH 8.0). The harvested cell culture supernatant was then diluted 1:1 with 2x the above buffer and filter sterilized. The filtered supernatant was incubated with the protein A column for 2 hours at room temperature.
  • IgG was eluted with sterile 0.1 M sodium citrate (pH 3.5), and the eluate was collected and washed with 1/9. Neutralize with one volume of sterile 1M Tris-HCl (pH 9.0). Under sterile conditions, the product was buffer exchanged to PBS (pH 7.4) to remove residual elution buffer and antibodies were quantified by OD280nm using an extinction coefficient Ec (0.1%) of 1.43.
  • Example 5 EC50 test of monoclonal antibody binding to viral N protein
  • Indirect ELISA was used to assess the binding ability of purified antibodies to N-ECD protein.
  • ELISA plates were coated with 100 ⁇ l/well of recombinant N-ECD protein at 0.5 ⁇ g/ml in PBS overnight at 4°C. Plates were washed with PBS-T (0.05% Tween) and blocked with 250 ⁇ l/well of PBST containing 1% BSA for 2 hours at 37°C. Subsequently, the blocking solution was discarded, and 100 ⁇ l of 1 ⁇ g/ml purified antibody was added to the first well, and diluted according to a 3-fold gradient, for a total of 7 test concentration gradients plus a blank well. It was then incubated at 37°C for 1 hour.
  • Antibody EC50 (ng/ml) RN1279 4.086 RN8105 4.129 RN5502 4.499 RN1248 4.697 RN0510 5.053 RN1245 5.425 RN2604 5.590
  • ELISA Competition ELISA was used to assess epitopes of cell culture supernatants.
  • ELISA plates were coated with 100 ⁇ l/well of 1 ⁇ g/ml recombinant N protein in PBS for 2 hours at 37°C. Plates were washed with PBS-T (0.05% Tween) and blocked with 250 ⁇ l/well of PBST containing 1% BSA for 1 hour at 37°C. The blocking solution was then discarded, and 50 ⁇ l of each cell supernatant premixed with horseradish peroxidase-conjugated goat anti-rabbit IgG (Fc-specific) (GenScript, A01856) secondary antibody was added to each well and each cell 50 ⁇ l of supernatant stock solution.
  • Fc-specific horseradish peroxidase-conjugated goat anti-rabbit IgG
  • Epitope 1 Epitope 2
  • Epitope 3 Epitope 4
  • Epitope 5 RN8105 RN1248 RN0510 RN2604 RN5502 / RN1245 RN1279 / /
  • ELISA plates were coated with 100 ⁇ l/well of 2.5 ⁇ g/ml of unlabeled purified antibody (eg NR8105) in PBS overnight at 4°C. Plates were washed with PBST (0.05% Tween) and blocked with 250 ⁇ l/well of PBST containing 1% BSA for 2 hours at 37°C. Subsequently, the blocking solution was discarded, and 100 ⁇ l of dilution solution with a concentration of 40 ng/ml in the first well, a 2-fold dilution concentration and a blank control group without recombinant N protein were added respectively, as shown in the first column of Table 4.
  • PBST 0.05% Tween
  • the plate was washed 4 times with PBST, and 1 ⁇ g/ml of a biotin-labeled antibody (such as Biotin-RN1245) was added to the wells of the plate, 100 ⁇ l per well, and incubated at 37°C for 1 hour. Plates were washed 4 times with PBST and incubated with 100 ⁇ l/well of streptavidin HRP (SA-HRP, GenScript) for 15 minutes at 37°C. Plates were finally washed 4 times with PBST, then TMB developer solution (GenScript) was added and incubated at 25°C for 15 minutes in the dark. The reaction was stopped by adding 50 ⁇ l of 1 M HCl stop solution (GenScript).
  • a biotin-labeled antibody such as Biotin-RN1245
  • the plate was read at 450 nm using a microplate reader.
  • the reaction color was developed, and the plate was read at 450 nm using a microplate reader.
  • the specific OD values are shown in Table 4. We randomly detected 20 blank controls and the variance was 0.018, so we thought that the OD value higher than the blank control group was 0.018 to be judged as a detection signal.
  • NR8105 and RN1245 can still detect a higher signal value than the control well when the antigen is diluted to 39.063 pg/ml (0.152>0.119+0.018), so the detection sensitivity of the paired antibody to the antigen is determined as 0-40pg/ml, the inspection curve is shown in Figure 4; for the same reason, NR8105 and RN2604 can still detect higher signal values than control wells when the antigen is diluted to 78.125pg/ml (0.119>0.090+0.018), so RN8105 and RN2604
  • the detection sensitivity is 40-80pg/ml, and the detection curve is shown in Figure 5. It can be used as the development of an ELISA kit for double-antibody sandwich detection of antigens.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention appartient au domaine de la détection et du diagnostic viraux, et concerne un anticorps monoclonal contre la protéine nucléocapsidique (protéine N) du virus SARS-CoV-2, ainsi que son procédé de préparation et son utilisation. La présente invention concerne un anticorps monoclonal contre la protéine N du SARS-CoV-2, ainsi que son procédé de préparation et son utilisation. L'anticorps monoclonal contre la protéine N du SARS-CoV-2 peut se lier à une protéine N et peut être utilisé pour détecter des antigènes du virus du SARS-CoV-2. L'anticorps monoclonal de la présente invention peut reconnaître cinq épitopes d'un antigène, et la diversité de l'anticorps facilite le développement d'un kit de détection. En outre, la sensibilité de la détection d'une protéine N recombinée purifiée au moyen de l'appariement des anticorps monoclonaux NR8105 et NR1245 fournis peut atteindre 0 à 40 pg/ml.
PCT/CN2022/077540 2021-02-24 2022-02-24 Anticorps monoclonal contre la protéine nucléocapsidique du sars-cov-2, son procédé de préparation et son utilisation WO2022179535A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110205067.9 2021-02-24
CN202110205067 2021-02-24

Publications (1)

Publication Number Publication Date
WO2022179535A1 true WO2022179535A1 (fr) 2022-09-01

Family

ID=83047889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/077540 WO2022179535A1 (fr) 2021-02-24 2022-02-24 Anticorps monoclonal contre la protéine nucléocapsidique du sars-cov-2, son procédé de préparation et son utilisation

Country Status (1)

Country Link
WO (1) WO2022179535A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115894675A (zh) * 2023-02-03 2023-04-04 康复大学(筹) 新冠病毒SARS-CoV-2核衣壳蛋白单克隆抗体及其应用
CN117659180A (zh) * 2022-09-06 2024-03-08 东莞市朋志生物科技有限公司 抗新型冠状病毒抗体或其功能性片段、检测新型冠状病毒的试剂和试剂盒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170051053A1 (en) * 2011-12-28 2017-02-23 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
CN111560070A (zh) * 2020-05-27 2020-08-21 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒np蛋白的抗体及其检测应用
CN111875700A (zh) * 2020-07-28 2020-11-03 武汉华美生物工程有限公司 抗sars-cov-2病毒n蛋白的单链抗体及其用途
CN112079920A (zh) * 2020-09-18 2020-12-15 北京华大蛋白质研发中心有限公司 一种用于检测SARS-CoV-2病毒N蛋白的单克隆抗体及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170051053A1 (en) * 2011-12-28 2017-02-23 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
CN111560070A (zh) * 2020-05-27 2020-08-21 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒np蛋白的抗体及其检测应用
CN111875700A (zh) * 2020-07-28 2020-11-03 武汉华美生物工程有限公司 抗sars-cov-2病毒n蛋白的单链抗体及其用途
CN112079920A (zh) * 2020-09-18 2020-12-15 北京华大蛋白质研发中心有限公司 一种用于检测SARS-CoV-2病毒N蛋白的单克隆抗体及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WANG GAI; CHANG HAIYAN; JIA BEI; LIU YONG; HUANG RUI; WU WEIHUA; HAO YINGYING; YAN XIAOMIN; XIA JUAN; CHEN YUXIN; WU CHAO: "Nucleocapsid protein-specific IgM antibody responses in the disease progression of severe fever with thrombocytopenia syndrome", TICKS AND TICK-BORNE DISEASES, vol. 10, no. 3, 1 April 2019 (2019-04-01), AMSTERDAM, NL , pages 639 - 646, XP085648695, ISSN: 1877-959X, DOI: 10.1016/j.ttbdis.2019.02.003 *
ZHU HAN-PING , ZHU ZHI-YONG, DONG GUAN-MU, YAO PING-PING, AN QI, WENG JING-QING,;LU YI-YU,XU FANG, LU QUN-YING, YAN JU-YING, GE QI: "An immunofluorescence assay for the detection of SARS associated coronavirus antibody based on recombinant nucleocapsid antigen and its application", NATIONAL MEDICAL JOURNAL OF CHINA, vol. 85, no. 9, 2 March 2005 (2005-03-02), pages 621 - 624, XP055962024 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117659180A (zh) * 2022-09-06 2024-03-08 东莞市朋志生物科技有限公司 抗新型冠状病毒抗体或其功能性片段、检测新型冠状病毒的试剂和试剂盒
CN115894675A (zh) * 2023-02-03 2023-04-04 康复大学(筹) 新冠病毒SARS-CoV-2核衣壳蛋白单克隆抗体及其应用
CN115894675B (zh) * 2023-02-03 2023-11-14 康复大学(筹) 新冠病毒SARS-CoV-2核衣壳蛋白单克隆抗体及其应用

Similar Documents

Publication Publication Date Title
CN111690058B (zh) 针对冠状病毒的具有中和活性的抗体及其用途
WO2022179535A1 (fr) Anticorps monoclonal contre la protéine nucléocapsidique du sars-cov-2, son procédé de préparation et son utilisation
WO2016127912A1 (fr) Anticorps pcsk9, et composition pharmaceutique et utilisation de celui-ci
WO2021098822A1 (fr) Anticorps bispécifiques
CN115724958B (zh) 抗诺如病毒gⅱ基因组衣壳蛋白vp1的单克隆抗体及其应用
TW202206455A (zh) 一種抗新型冠狀病毒的單克隆抗體及其應用
WO2016173559A1 (fr) Préparation et utilisation de l'anticorps monoclonal murin contre le norovirus gi.1
CN113817052A (zh) 抗SARS-CoV-2核衣壳蛋白单克隆抗体及其制备方法和用途
WO2019128120A1 (fr) Anticorps neutralisant entièrement humain pour la lutte contre la toxine tétanique
WO2021238854A1 (fr) Anticorps monoclonal dirigé contre la protéine de spicule du sars-cov-2, son procédé de préparation et son utilisation
WO2021233433A1 (fr) Anticorps monoclonal anti-protéine de spicule du sars-cov-2
CN115315442A (zh) Sars-cov-2抗体及其应用
CN115087667B (zh) 特异性结合SARS-CoV-2的抗原结合蛋白
WO2023005805A1 (fr) Polypeptide épitope d'affinité générale pour rhinovirus humain, anticorps et leurs utilisations
WO2023206609A1 (fr) Anticorps dirigé contre p-tau 217 et son utilisation
WO2022102744A1 (fr) Anticorps visant la protéine de spicule du sars-cov-2
WO2022068895A1 (fr) Anticorps monoclonal dirigé contre le domaine extracellulaire de la protéine de spicule du sars-cov-2, et son utilisation
CN114703147A (zh) 一种抗SARS-CoV-2广谱中和性单克隆抗体及其杂交瘤细胞株、检测试剂盒和应用
CN112225804A (zh) 纳米抗体及其应用
WO2023046057A1 (fr) Anticorps monoclonal dirigé contre le mutant l452r de protéine de spicule de sars-cov-2 et son utilisation
RU2803082C2 (ru) Антитела против вируса гепатита в и их применение
WO2022095996A1 (fr) Anticorps anti-sars-cov-2 et son utilisation
US20220251173A1 (en) Anti-hepatitis b virus antibodies and use thereof
WO2023046039A1 (fr) Anticorps monoclonal de protéine de spicule e484q anti-sars-cov-2 et son utilisation
WO2024085207A1 (fr) Antisérum équin contre le bêtacoronavirus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22758899

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22758899

Country of ref document: EP

Kind code of ref document: A1